The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

被引:4
作者
Batgi, Hikmettullah [1 ,2 ]
Merdin, Alparslan [1 ,2 ]
Sinan Dal, Mehmet [1 ,2 ]
Kizil Cakar, Merih [1 ,2 ]
Yildiz, Jale [1 ,2 ]
Basci, Semih [1 ,2 ]
Uncu Ulu, Bahar [1 ,2 ]
Yigenoglu, Tugce Nur [1 ,2 ]
Darcin, Tahir [1 ,2 ]
Sahin, Derya [1 ,2 ]
Bakirtas, Mehmet [1 ,2 ]
Tetik, Aysegul [1 ,2 ]
Iskender, Dicle [1 ,2 ]
Altuntas, Fevzi [1 ,2 ]
机构
[1] Univ Hlth Sci, Dept Hematol, Ankara Dr Abdurrahman Yurtaslan Oncol Training &, Ankara, Turkey
[2] Univ Hlth Sci, Stem Cell Transplantat Clin, Ankara Dr Abdurrahman Yurtaslan Oncol Training &, Ankara, Turkey
关键词
GDP; relapsed; refractory Hodgkin lymphoma; refractory non-Hodgkin lymphoma; STEM-CELL-TRANSPLANTATION; NATIONAL-CANCER-INSTITUTE; NON-HODGKIN-LYMPHOMA; RESPONSE CRITERIA; PROGNOSTIC SCORE; SALVAGE THERAPY; PHASE-II; CYTARABINE; RECURRENT; SURVIVAL;
D O I
10.1177/1078155220905654
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The optimal choice of salvage therapy for patients with relapsed/refractory non-Hodgkin lymphoma or Hodgkin lymphoma remains controversial. In this study, we aimed to share our experience in relapsed/refractory lymphoma patients who received GDP/R-GDP as salvage chemotherapy in our center. Data of 47 relapsed/refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients who received GDP or R-GDP as salvage chemotherapy in our center between July 2014 and October 2017 were retrospectively evaluated. Non-Hodgkin lymphoma and Hodgkin lymphoma patients were divided into two groups as primary refractory and relapsed. The one-year overall survival was 100% (for relapsed) and 36.9% (for refractory) in the non-Hodgkin lymphoma groups, and 82.5% (for relapsed) and 80% (for refractory) in the Hodgkin lymphoma group. The one-year progression-free survival (PFS) was 72.7% (for relapsed) and 38.5% (for refractory) in patients with NHL, and 41% (for relapsed) and 18.2% (for refractory) in patients with HL. GDP/R-GDP seems to be a well-tolerated out-patient salvage regimen for relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma. Although proven efficacy, negative toxicity profile, and ease of administration, the application of gemcitabine-based therapy for patients with primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma provided limited success.
引用
收藏
页码:1857 / 1863
页数:7
相关论文
共 20 条
[1]   Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 [J].
Al-Hamadani, Mohammed ;
Habermann, Thomas M. ;
Cerhan, James R. ;
Macon, William R. ;
Maurer, Matthew J. ;
Go, Ronald S. .
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (09) :790-795
[2]   Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group [J].
Baetz, T ;
Belch, A ;
Couban, S ;
Imrie, K ;
Yau, J ;
Myers, R ;
Ding, K ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R ;
Crump, M .
ANNALS OF ONCOLOGY, 2003, 14 (12) :1762-1767
[3]   Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias [J].
Cheson, BD ;
Vena, DA ;
Barrett, J ;
Freidlin, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2454-2460
[4]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[5]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[6]   Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma - A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [J].
Crump, M ;
Baetz, T ;
Couban, S ;
Belch, A ;
Marcellus, D ;
Howson-Jan, K ;
Imrie, K ;
Myers, R ;
Adams, G ;
Ding, KY ;
Paul, N ;
Shepherd, L ;
Iglesias, J ;
Meyer, R .
CANCER, 2004, 101 (08) :1835-1842
[7]   Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12 [J].
Crump, Michael ;
Kuruvilla, John ;
Couban, Stephen ;
MacDonald, David A. ;
Kukreti, Vishal ;
Kouroukis, C. Tom ;
Rubinger, Morel ;
Buckstein, Rena ;
Imrie, Kevin R. ;
Federico, Massimo ;
Di Renzo, Nicola ;
Howson-Jan, Kang ;
Baetz, Tara ;
Kaizer, Leonard ;
Voralia, Michael ;
Olney, Harold J. ;
Turner, A. Robert ;
Sussman, Jonathan ;
Hay, Annette E. ;
Djurfeldt, Marina S. ;
Meyer, Ralph M. ;
Chen, Bingshu E. ;
Shepherd, Lois E. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) :3490-+
[8]   Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].
Gisselbrecht, Christian ;
Glass, Bertram ;
Mounier, Nicolas ;
Gill, Devinder Singh ;
Linch, David C. ;
Trneny, Marek ;
Bosly, Andre ;
Ketterer, Nicolas ;
Shpilberg, Ofer ;
Hagberg, Hans ;
Ma, David ;
Briere, Josette ;
Moskowitz, Craig H. ;
Schmitz, Norbert .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190
[9]   A prognostic score for advanced Hodgkin's disease [J].
Hasenclever, D ;
Diehl, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1506-1514
[10]  
Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.21254]